Royal Bank of Canada’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $43K | Buy |
12,230
+4,158
| +52% | +$14.6K | ﹤0.01% | 5610 |
|
|
2025
Q1 | $24K | Sell |
8,072
-2,771
| -26% | -$8.24K | ﹤0.01% | 5467 |
|
|
2024
Q4 | $37K | Buy |
10,843
+715
| +7% | +$2.44K | ﹤0.01% | 5343 |
|
|
2024
Q3 | $34K | Buy |
10,128
+2,871
| +40% | +$9.64K | ﹤0.01% | 5400 |
|
|
2024
Q2 | $24K | Buy |
7,257
+4,087
| +129% | +$13.5K | ﹤0.01% | 5592 |
|
|
2024
Q1 | $13K | Sell |
3,170
-26,439
| -89% | -$108K | ﹤0.01% | 5640 |
|
|
2023
Q4 | $91K | Buy |
29,609
+15,585
| +111% | +$47.9K | ﹤0.01% | 5139 |
|
|
2023
Q3 | $42K | Buy |
14,024
+6,026
| +75% | +$18K | ﹤0.01% | 5379 |
|
|
2023
Q2 | $30K | Buy |
7,998
+2,224
| +39% | +$8.34K | ﹤0.01% | 5548 |
|
|
2023
Q1 | $19K | Sell |
5,774
-4,890
| -46% | -$16.1K | ﹤0.01% | 5654 |
|
|
2022
Q4 | $52K | Buy |
10,664
+6,128
| +135% | +$29.9K | ﹤0.01% | 5382 |
|
|
2022
Q3 | $26K | Buy |
4,536
+2,507
| +124% | +$14.4K | ﹤0.01% | 5548 |
|
|
2022
Q2 | $15K | Sell |
2,029
-3,539
| -64% | -$26.2K | ﹤0.01% | 5746 |
|
|
2022
Q1 | $41K | Sell |
5,568
-5,681
| -51% | -$41.8K | ﹤0.01% | 5730 |
|
|
2021
Q4 | $100K | Buy |
11,249
+3,002
| +36% | +$26.7K | ﹤0.01% | 5405 |
|
|
2021
Q3 | $290K | Buy |
8,247
+2,090
| +34% | +$73.5K | ﹤0.01% | 4317 |
|
|
2021
Q2 | $133K | Buy |
6,157
+5,180
| +530% | +$112K | ﹤0.01% | 4932 |
|
|
2021
Q1 | $60K | Buy |
977
+615
| +170% | +$37.8K | ﹤0.01% | 5289 |
|
|
2020
Q4 | $15K | Buy |
+362
| New | +$15K | ﹤0.01% | 5634 |
|